We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

End Of Fosamax Patent Heralds Payday For Generics

Law360 (February 7, 2008, 12:00 AM EST) -- Patent protection for Merck & Co.'s Fosamax expired on Wednesday, giving other pharmaceutical companies the thumbs-up to start marketing generic versions of the popular osteoporosis drug.

Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals both said they had received approval from the U.S. Food and Drug Administration to market generic versions of Fosamax.

Teva announced Wednesday that it would begin marketing the drug in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg tablets. Shipment of the product will begin immediately, the company said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.